Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5297 | 2021 |
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1333 | 2021 |
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 740 | 2021 |
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 660* | 2021 |
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 576* | 2021 |
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a … ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews, ... The Lancet 399 (10319), 36-49, 2022 | 214 | 2022 |
An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate … CS Waddington, TC Darton, C Jones, K Haworth, A Peters, T John, ... Clinical Infectious Diseases 58 (9), 1230-1240, 2014 | 154 | 2014 |
Design, recruitment, and microbiological considerations in human challenge studies TC Darton, CJ Blohmke, VS Moorthy, DM Altmann, FG Hayden, ... The Lancet infectious diseases 15 (7), 840-851, 2015 | 138 | 2015 |
Severity of meningococcal disease associated with genomic bacterial load T Darton, M Guiver, S Naylor, DL Jack, EB Kaczmarski, R Borrow, ... Clinical infectious diseases 48 (5), 587-594, 2009 | 138 | 2009 |
Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 134 | 2021 |
Ethics of controlled human infection to address COVID-19 SK Shah, FG Miller, TC Darton, D Duenas, C Emerson, HF Lynch, ... Science 368 (6493), 832-834, 2020 | 128 | 2020 |
Epidemiology and control of tuberculosis in Western European cities AC Hayward, T Darton, JN Van-Tam, JM Watson, R Coker, V Schwoebel The international journal of tuberculosis and lung disease 7 (8), 751-757, 2003 | 97 | 2003 |
Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a TC Darton, C Jones, CJ Blohmke, CS Waddington, L Zhou, A Peters, ... PLoS neglected tropical diseases 10 (8), e0004926, 2016 | 86 | 2016 |
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire PA Swanson, M Padilla, W Hoyland, K McGlinchey, PA Fields, S Bibi, ... Science translational medicine 13 (620), eabj7211, 2021 | 74 | 2021 |
Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies CS Waddington, TC Darton, WE Woodward, B Angus, MM Levine, ... Journal of Infection 68 (5), 405-418, 2014 | 74 | 2014 |
The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance … TC Darton, JE Meiring, S Tonks, MA Khan, F Khanam, M Shakya, ... BMJ open 7 (6), e016283, 2017 | 72 | 2017 |
Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model HC Dobinson, MM Gibani, C Jones, HB Thomaides-Brears, M Voysey, ... Clinical Infectious Diseases 64 (8), 1066-1073, 2017 | 70 | 2017 |
Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans S Fresnay, MA McArthur, L Magder, TC Darton, C Jones, CS Waddington, ... Journal of translational medicine 14, 1-14, 2016 | 68 | 2016 |